Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.58 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.58 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | GGH | Q92820 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387298 | 1.00 | NAALAD2 (0.60) | NAALAD2FOLH1MEP1BCPA3GGH | |
| SCHEMBL1818651 | 1.00 | NAALAD2 (0.60) | NAALAD2FOLH1MEP1BCPA3GGH | |
| SCHEMBL30213700 | 0.91 | NAALAD2 (0.51) | NAALAD2FOLH1MEP1BCPA3GGH | |
| SCHEMBL31419850 | 0.88 | MEP1B (0.61) | NAALAD2FOLH1MEP1BCPA3GGH | |
| SCHEMBL461572 | 0.87 | KMT2A (0.54) | NAALAD2FOLH1MEP1BMMP9MMP8 | |
| SCHEMBL461571 | 0.87 | KMT2A (0.54) | NAALAD2FOLH1MEP1BMMP9MMP8 | |
| SCHEMBL2251929 | 0.87 | MEP1B (0.52) | NAALAD2FOLH1MEP1BCPA3GGH | |
| SCHEMBL5577139 | 0.85 | MEP1B (0.48) | NAALAD2FOLH1MEP1BGGHRIMKLA | |
| SCHEMBL5577137 | 0.85 | MEP1B (0.48) | NAALAD2FOLH1MEP1BGGHRIMKLA | |
| SCHEMBL6566486 | 0.85 | FOLH1 (0.61) | NAALAD2FOLH1MEP1BGAAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746923-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2026-05-27 | — | — | EP | claimed |
| CN-122075810-A | Collagen anti-corrosion coating with tissue repair performance, preparation method and application | — | 2026-05-26 | — | — | CN | claimed |
| US-12558308-B2 | Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents | C.R. BARD, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4683929-A1 | STIMULUS RESPONSIVE NANOCOMPOSITES | University of Delaware (US) | 2026-01-28 | — | — | EP | claimed |
| US-12440447-B2 | Drug-loaded microbead compositions, embolization compositions and associated methods | C.R. BARD, INC. (US) | 2025-10-14 | — | — | US | claimed |
| CN-119454998-A | Hypoxia responsive nuclear crosslinking supermolecule nano prodrug based on dendritic drug-drug conjugate, and preparation method and application thereof | 南通大学 | 2025-02-18 | — | — | CN | claimed |
| WO-2025017370-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2025-01-23 | — | — | WO | claimed |
| EP-4493219-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP Technologies, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2024197269-A1 | STIMULUS RESPONSIVE NANOCOMPOSITES | JANG DASEUL (US) | 2024-09-26 | — | — | WO | claimed |
| CN-115888659-B | New preparation method of macroporous cyclodextrin microsphere for flavone separation | 四川聚豪锦悦农林科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| JP-H08501286-A | — | — | 1996-02-13 | — | — | JP | claimed |
| WO-1995025984-A1 | BIOPOLYMER-BASED NONLINEAR OPTICAL MATERIALS | CAMBRIDGE SCIENTIFIC, INC. (US) | 1995-09-28 | — | — | WO | claimed |
| EP-0649302-A1 | THERAPEUTIC AND DIAGNOSTIC USE OF MODIFIED POLYMERIC MICROCAPSULES | WALLACE, Sidney (US) | 1995-04-26 | — | — | EP | claimed |
| WO-1994002106-A1 | THERAPEUTIC AND DIAGNOSTIC USE OF MODIFIED POLYMERIC MICROCAPSULES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-02-03 | — | — | WO | claimed |
| US-5243451-A | DAP type liquid crystal device with cholesteric liquid crystal birefringent layer | RICOH COMPANY, LTD. (JP) | 1993-09-07 | — | — | US | claimed |
| EP-0553299-A1 | EFFICIENT MICROCAPSULE PREPARATION AND METHOD OF USE. | UNIV TEXAS (US) | 1993-08-04 | — | — | EP | claimed |
| US-5124437-A | High-molecular-weight missile drug carriers | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-06-23 | — | — | US | claimed |
| WO-1992005866-A2 | EFFICIENT MICROCAPSULE PREPARATION AND METHOD OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0213996-B1 | RAMIFIED POLYMERS BASED ON LIPOPEPTIDES FORMING THERMOTROPIC AND LYOTROPIC LIQUID CRYSTALS, THEIR USE AND CORRESPONDING MONOMERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-09-06 | — | — | EP | claimed |
| EP-0085255-A2 | N-acyl peptide, processes for their preparation and pharmaceutical compostions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-08-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558308-B2 | Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents | CHMP4B, CD44, LIPA | NAALAD2 1443/4885FOLH1 2073/4885MEP1B 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.